
Vivos Therapeutics (VVOS) Stock Forecast & Price Target
Vivos Therapeutics (VVOS) Analyst Ratings
Bulls say
Vivos Therapeutics is well-positioned for long-term success due to positive factors such as a higher share count, strong gross margins, and a multi-billion-dollar market potential. They are actively developing their channel and offering through collaborations and partnerships, potentially leading to high profitability. However, an additional capital infusion may be needed in 2026 and expenses may be temporarily higher due to the transition to a new business model. Despite these risks, the company's potential for strong financial performance in the long-term remains high.
Bears say
Vivos Therapeutics is facing challenges, as its gross margins are trending higher, but there is a lack of clarity on its steady-state gross margin. Despite this, the company's new treatment option, the Vivos System, shows promise in addressing the limited treatment times, durability, and potential symptom reversal of sleep apnea. This is reflected in the company's projections, with a 12-month price target of $3.00 derived from a comparable universe analysis and an EV/Revenue multiple of 3.0x. However, there are risks to reaching this target, including lower than expected sales growth, competition, and regulatory concerns. Additionally, the company's share price target may be impacted by balance sheet/liquidity risks, failure to gain regulatory approvals, and changing macroeconomic factors.
This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Vivos Therapeutics (VVOS) Analyst Forecast & Price Prediction
Start investing in Vivos Therapeutics (VVOS)
Order type
Buy in
Order amount
Est. shares
0 shares